Levothyroxine treatment
PreclinicalSmall molecule
Levothyroxine treatment is one of 9 small molecule programs targeting Hypothyroidism. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hypothyroidism
#DrugCompanyPhaseTrials
1Synthroid
IInstitut Jerome Lejeune
Approved
Tricor
JJagotec
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Levothyroxin
BBerlin-Chemie AG Menarini Group
Phase 3
Armour Thyroid
AbbViePhase 3
Triostat
VViking Therapeutics, Inc.
Preclinical
Medication
NNYU Langone Health
Preclinical
Thyrotropin-Releasing Hormone
NNational Center for Research Resources (NCRR)
Preclinical
Levothyroxine treatment
HHerlev Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Levothyroxine treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHerlev Hospital